{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:30:47Z","timestamp":1786995047467,"version":"build-2736575974"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"vor","delay-in-days":62,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004937","name":"Bundesministerium fur Bildung und Forschung Dienststelle Berlin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01EN2006A\/B"],"award-info":[{"award-number":["01EN2006A\/B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience Applied"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.nsa.2022.100104","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T02:32:28Z","timestamp":1646620348000},"page":"100104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) \u2013 Rationale and study design"],"prefix":"10.1016","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4415-3941","authenticated-orcid":false,"given":"Lea J.","family":"Mertens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8798-9875","authenticated-orcid":false,"given":"Michael","family":"Koslowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1389-4870","authenticated-orcid":false,"given":"Felix","family":"Betzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricarda","family":"Evens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gilles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Jungaberle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7634-4211","authenticated-orcid":false,"given":"Henrik","family":"Jungaberle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomislav","family":"Maji\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Str\u00f6hle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6896-9633","authenticated-orcid":false,"given":"Max","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Wellek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Gr\u00fcnder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nsa.2022.100104_bib1","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1177\/0269881116678781","article-title":"The challenging experience questionnaire: characterization of challenging experiences with psilocybin mushrooms","volume":"30","author":"Barrett","year":"2016","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.nsa.2022.100104_bib2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1192\/bjp.bp.114.150136","article-title":"Efficacy of selective serotonin reuptake inhibitors and adverse events: meta-regression and mediation analysis of placebo-controlled trials","volume":"208","author":"Barth","year":"2016","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.nsa.2022.100104_bib3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0272-7358(88)90050-5","article-title":"Psychometric properties of the beck depression inventory: twenty-five years of evaluation","volume":"8","author":"Beck","year":"1988","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.nsa.2022.100104_bib4","series-title":"Childhood Trauma Questionnaire: A Retrospective Self-Report Manual","author":"Bernstein","year":"1998"},{"key":"10.1016\/j.nsa.2022.100104_bib5","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.nsa.2022.100104_bib6","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/jmt\/9.2.64","article-title":"The use of music in psychedelic (LSD) psychotherapy","volume":"9","author":"Bonny","year":"1972","journal-title":"J.\u00a0Music Ther."},{"key":"10.1016\/j.nsa.2022.100104_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1467-9574.1970.tb00104.x","article-title":"Raised conditional level of significance for the 2 \u00d7 2-table when testing the equality of two probabilities","volume":"24","author":"Boschloo","year":"1970","journal-title":"Stat. Neerl."},{"key":"10.1016\/j.nsa.2022.100104_bib8","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1037\/0022-3514.84.4.822","article-title":"The benefits of being present: mindfulness and its role in psychological well-being","volume":"84","author":"Brown","year":"2003","journal-title":"J.\u00a0Pers. Soc. Psychol."},{"key":"10.1016\/j.nsa.2022.100104_bib9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3109\/00952990.2013.811513","article-title":"A\u00a0proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment","volume":"39","author":"Burdick","year":"2013","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.nsa.2022.100104_bib10","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-020-3008-z","article-title":"A\u00a0non-hallucinogenic psychedelic analogue with therapeutic potential","volume":"589","author":"Cameron","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.nsa.2022.100104_bib11","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatr."},{"key":"10.1016\/j.nsa.2022.100104_bib12","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.nsa.2022.100104_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0192761","article-title":"Population-based validation of a German version of the brief resilience scale","volume":"13","author":"Chmitorz","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.nsa.2022.100104_bib14","series-title":"Wiley StatsRef: Statistics Reference Online","article-title":"Assay sensitivity","author":"Chuang-Stein","year":"2014"},{"key":"10.1016\/j.nsa.2022.100104_bib15","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.nsa.2022.100104_bib16","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","article-title":"Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial","volume":"75","author":"Daly","year":"2018","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.nsa.2022.100104_bib17","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatr."},{"issue":"Suppl. 2","key":"10.1016\/j.nsa.2022.100104_bib18","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1055\/s-2007-979351","article-title":"The standardized psychometric assessment of altered states of consciousness (ascs) in humans","volume":"31","author":"Dittrich","year":"1998","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.nsa.2022.100104_bib19","article-title":"Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)","author":"Fava","year":"2018","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.nsa.2022.100104_bib20","series-title":"Structured Clinical Interview for DSM-5 Screening Personality Questionnaire (SCID-5-SPQ)","author":"First","year":"2016"},{"key":"10.1016\/j.nsa.2022.100104_bib21","first-page":"407","article-title":"German version of the snaith-Hamilton-pleasure scale (SHAPS-D), Fortschr","volume":"66","author":"Franz","year":"1998","journal-title":"Neurol. Psychiatr."},{"key":"10.1016\/j.nsa.2022.100104_bib22","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S2215-0366(19)30217-2","article-title":"Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis","volume":"6","author":"Furukawa","year":"2019","journal-title":"Lancet Psychiatr."},{"key":"10.1016\/j.nsa.2022.100104_bib23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1037\/a0034473","article-title":"The brief experiential avoidance questionnaire: development and initial validation","volume":"26","author":"Gamez","year":"2014","journal-title":"Psychol. Assess."},{"key":"10.1016\/j.nsa.2022.100104_bib24","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.nsa.2022.100104_bib25","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00213-011-2358-5","article-title":"Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects","volume":"218","author":"Griffiths","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.nsa.2022.100104_bib26","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.nsa.2022.100104_bib27","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1055\/a-1520-5020","article-title":"Psychedelics: a new treatment paradigm in psychiatry?","volume":"54","author":"Gr\u00fcnder","year":"2021","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.nsa.2022.100104_bib28","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1055\/a-1486-7386","article-title":"The potential role of psychedelic drugs in mental health care of the future","volume":"54","author":"Gr\u00fcnder","year":"2021","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.nsa.2022.100104_bib29","first-page":"863","article-title":"Psilocybin for depression","volume":"385","author":"Gr\u00fcnder","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.nsa.2022.100104_bib30","first-page":"279","article-title":"The placebo problem","volume":"1","author":"Haas","year":"1959","journal-title":"Fortschr. Arzneimittelforsch."},{"key":"10.1016\/j.nsa.2022.100104_bib31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","article-title":"Long-term follow-up of psilocybin-facilitated smoking cessation","volume":"43","author":"Johnson","year":"2017","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.nsa.2022.100104_bib32","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00213-017-4820-5","article-title":"The hidden therapist: evidence for a central role of music in psychedelic therapy","volume":"235","author":"Kaelen","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.nsa.2022.100104_bib33","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/wps.20241","article-title":"Antidepressants versus placebo in major depression: an overview","volume":"14","author":"Khan","year":"2015","journal-title":"World Psychiatr."},{"key":"10.1016\/j.nsa.2022.100104_bib34","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1017\/S1121189X00000282","article-title":"Antidepressants and the placebo response","volume":"18","author":"Kirsch","year":"2009","journal-title":"Epidemiol. Psichiatr. Soc."},{"key":"10.1016\/j.nsa.2022.100104_bib35","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1742-1241.2005.00440.x","article-title":"Efficacy of escitalopram in patients with severe depression: a pooled analysis","volume":"59","author":"Llorca","year":"2005","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.nsa.2022.100104_bib36","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0191-8869(03)00118-1","article-title":"A\u00a0contemplated revision of the neo five-factor inventory","volume":"36 3","author":"McCrae","year":"2004","journal-title":"Pers. Indiv. Differ."},{"key":"10.1016\/j.nsa.2022.100104_bib37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/009262300278623","article-title":"The Arizona sexual experience scale (ASEX): reliability and validity","volume":"26","author":"McGahuey","year":"2000","journal-title":"J.\u00a0Sex Marital Ther."},{"key":"10.1016\/j.nsa.2022.100104_bib38","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1055\/a-1341-1907","article-title":"Classical psychedelics as therapeutics in psychiatry - current clinical evidence and potential therapeutic mechanisms in substance use and mood disorders","volume":"54","author":"Mertens","year":"2021","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.nsa.2022.100104_bib39","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S2215-0366(18)30135-4","article-title":"3,4-methylenedioxymethamphetamine (mdma)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial","volume":"5","author":"Mithoefer","year":"2018","journal-title":"Lancet Psychiatr."},{"key":"10.1016\/j.nsa.2022.100104_bib40","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/17512433.2021.1933434","article-title":"Blinding and expectancy confounds in psychedelic randomized controlled trials","volume":"14","author":"Muthukumaraswamy","year":"2021","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.nsa.2022.100104_bib41","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.concog.2014.01.006","article-title":"The free will inventory: measuring beliefs about agency and responsibility","volume":"25","author":"Nadelhoffer","year":"2014","journal-title":"Conscious. Cognit."},{"key":"10.1016\/j.nsa.2022.100104_bib42","first-page":"1","article-title":"Psilocybin for depression: considerations for clinical trial design","author":"O'Donnell","year":"2019","journal-title":"J.\u00a0Psychedelic Stud."},{"issue":"3","key":"10.1016\/j.nsa.2022.100104_bib43","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0005-7967(03)00140-2","article-title":"Avoidance and depression: the construction of the Cognitive\u2013Behavioral Avoidance Scale","volume":"42","author":"Ottenbreit","year":"2004","journal-title":"Behav. Res. Ther."},{"key":"10.1016\/j.nsa.2022.100104_bib44","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3389\/fphar.2017.00974","article-title":"Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression","volume":"8","author":"Roseman","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.nsa.2022.100104_bib45","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1177\/0269881119855974","article-title":"Emotional breakthrough and psychedelics: validation of the emotional breakthrough inventory","volume":"33","author":"Roseman","year":"2019","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.nsa.2022.100104_bib46","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0006-3223(98)00126-7","article-title":"Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial","volume":"44","author":"Rosenbaum","year":"1998","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.nsa.2022.100104_bib47","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.nsa.2022.100104_bib48","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.neuropharm.2017.12.040","article-title":"Psychiatry & the psychedelic drugs. Past, present & future","volume":"142","author":"Rucker","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.nsa.2022.100104_bib49","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1093\/ije\/dyy076","article-title":"Impact of placebo arms on outcomes in antidepressant trials: systematic review and meta-regression analysis","volume":"47","author":"Salanti","year":"2018","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.nsa.2022.100104_bib50","series-title":"Wortschatztest: WST","author":"Schmidt","year":"1992"},{"key":"10.1016\/j.nsa.2022.100104_bib51","series-title":"German Version of the Grid Hamilton Rating Scale for Depression","author":"Schmitt","year":"2015"},{"key":"10.1016\/j.nsa.2022.100104_bib52","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.biopsych.2015.10.018","article-title":"Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study","volume":"80","author":"Singh","year":"2016","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.nsa.2022.100104_bib53","article-title":"The meaning in life questionnaire: assessing the presence of and search for meaning in life","volume":"53","author":"Steger","year":"2006","journal-title":"J.\u00a0Counsel. Psychol."},{"key":"10.1016\/j.nsa.2022.100104_bib54","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/stan.12063","article-title":"Nearly exact sample size calculation for powerful non-randomized tests for differences between binomial proportions","volume":"69","author":"Wellek","year":"2015","journal-title":"Stat. Neerl."}],"container-title":["Neuroscience Applied"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772408522001041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772408522001041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T11:48:58Z","timestamp":1778932138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772408522001041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":54,"alternative-id":["S2772408522001041"],"URL":"https:\/\/doi.org\/10.1016\/j.nsa.2022.100104","relation":{},"ISSN":["2772-4085"],"issn-type":[{"value":"2772-4085","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) \u2013 Rationale and study design","name":"articletitle","label":"Article Title"},{"value":"Neuroscience Applied","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nsa.2022.100104","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V. on behalf of European College of Neuropsychopharmacology.","name":"copyright","label":"Copyright"}],"article-number":"100104"}}